[When is antivitamin K therapy indicated in the stable coronary patient?]

Area of Science:

• Cardiology
• Pharmacology
• Thrombosis

Context:

• Anticoagulant therapy is often indicated in cardiac patients due to co-existing conditions or thrombotic risks, not solely the cardiac disease.
• Conditions like abnormal rhythms, apical thrombus, or significant akinesis necessitate considering vitamin K antagonists.
• Decades of research inform the efficacy and risks of vitamin K antagonists in cardiovascular care.

Purpose:

• To review the indications and efficacy of vitamin K antagonists in cardiac patients.
• To highlight clinical situations and thrombogenic factors guiding the initiation of vitamin K antagonist therapy.
• To discuss the balance between therapeutic benefits and hemorrhagic risks associated with vitamin K antagonists.

Summary:

• Vitamin K antagonists are indicated in cardiac patients with specific thrombogenic risks such as abnormal rhythms or apical thrombi.
• High-dose vitamin K antagonists show good efficacy but carry significant hemorrhagic risks.
• Promising results emerge from studies combining low-dose aspirin with moderate-dose vitamin K antagonists (INR 2-2.5).

Impact:

• Provides guidance on appropriate use of vitamin K antagonists in complex cardiac cases.
• Emphasizes the importance of patient education for successful initiation and management of anticoagulant therapy.
• Suggests novel therapeutic strategies, like combined aspirin and moderate-dose vitamin K antagonists, warranting further investigation.